ARTICLE | Company News
MLNM, ILXO receive Campath approval
May 8, 2001 7:00 AM UTC
The FDA granted Millennium (MLNM) and Ilex (ILXO) marketing approval for Campath alemtuzumab to treat B cell chronic lymphocytic leukemia patients who have been treated with alkylating agents and have...